ArticleJournal of natural medicines2011
Red ginseng deregulates hypoxia-induced genes by dissociating the HIF-1 dimer.
Article in Journal of natural medicines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Cholesterol-modulating effects of Korean red ginseng (KRG) targeting PCSK9 in hyperlipidemia.Scientific reports · 2025Article
- A comprehensive review of medicinal plants and their beneficial roles in alleviating bisphenol A-induced organ toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Rg3-enriched red ginseng extracts enhance apoptosis in CoClJournal of ginseng research · 2024Article
- Crosstalk between hypoxic cellular micro-environment and the immune system: a potential therapeutic target for infectious diseases.Frontiers in immunology · 2023Article
- Pseudoginsengenin DQ exerts antitumour activity against hypopharyngeal cancer cells by targeting the HIF-1α-GLUT1 pathway.Cancer cell international · 2021Article
- Korean Red Ginseng extract reduces hypoxia-induced epithelial-mesenchymal transition by repressing NF-κB and ERK1/2 pathways in colon cancer.Journal of ginseng research · 2018Article
- EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers.Frontiers in pediatrics · 2018Review
- Implications of redJournal of ginseng research · 2017Review
- Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?Frontiers in pharmacology · 2013Article
- Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.Frontiers in pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Water extract of Korean red ginseng (KRGW) contains numerous bioactive ginsenosides and is very popular as a multi-purpose medicine for health improvement. KRGW has been in the limelight because of its clinical benefit in cancer control. A growing body of evidence suggests that hypoxia-inducible factor-1 (HIF-1) plays critical roles in tumor promotion under hypoxia and that it is a compelling target for cancer therapy. In this paper we investigated the effect of KRGW on HIF-1-mediated adaptation to hypoxia. In both Hep3B cancer and HEK293 immortalized normal cell lines, KRGW attenuated the expression of hypoxia-induced genes without apparent cytotoxicity. Mechanistically, KRGW did not affect the synthesis, degradation, and translocation of HIF-1 in hypoxia. Interestingly, KRGW was found to repress the transcriptional activity of HIF-1 by interfering with the dimerization between HIF-1α and aryl hydrocarbon receptor nuclear translocator. To identify the HIF-inhibiting ingredient(s), we examined the effects of major ginsenosides on HIF-1 activity, but all ginsenosides tested failed to inactivate HIF-1. Based on these results, we propose that HIF-1 inhibition underlies the anticancer effect of ginseng. It is also proposed that KRGW could be an anticancer drug targeting hypoxic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.